Pharmaceutical Pricing and Reimbursement in the United StatesDecision ResourcesDecember 15, 2006 48 Pages - SKU: DECR1399804 |
|
Outsourcing in Drug Discovery: The Contract Research Organization (CRO) Market, 5th Edition
5/11/2012 | published by: Kalorama Information
The drug discovery process is long, arduous and costly, which has driven outsourcing in this field. The first phase is discovery of a lead compound, a molecule that affects biological function by binding to a
|
more...
|
$3,995.00
|
|
Orphan Disease Therapeutics in Genetic Disorders to 2018 - Emerging Agents in Cystic Fibrosis Offer Strong Opportunities for Investment and Licensing Activity
5/15/2012 | published by: GBI Research
Orphan Disease Therapeutics in Genetic Disorders to 2018 - Emerging Agents in Cystic Fibrosis Offer Strong Opportunities for Investment and Licensing Activity
Summary
GBI Research, the leading
|
more...
|
$3,500.00
|
|
Out-of-Pocket Healthcare 2012
4/3/2012 | published by: Kalorama Information
Despite numerous attempts to reign in costs of healthcare, consumers are increasingly paying for healthcare products and services from their own monies. The costs of health care products and services continue
|
more...
|
$995.00
|
|
World Market for Prescription Dermatological Drugs, 8th Edition (Antiacne, Antiaging, Dermatitis, Hair Loss, Psoriasis, Skin Cancer, Melasma and Seborrhea Treatments)
3/1/2012 | published by: Kalorama Information
This Kalorama Information report, The Worldwide Market for Prescription Dermatological Drugs represents the eighth time that Kalorama has detailed the various categories of prescription dermatological drugs, describing the global market and identifying major market factors
|
more...
|
$3,995.00
|
|
Orphan Diseases Therapeutics in Oncology to 2018 - Strongly Diversified Developmental Pipelines Indicate Long-Term Growth Potential despite Moderate Scope of Current Late Stage Molecules
4/30/2012 | published by: GBI Research
Orphan Diseases Therapeutics in Oncology to 2018 - Strongly Diversified Developmental Pipelines Indicate Long-Term Growth Potential despite Moderate Scope of Current Late Stage Molecules Summary GBI Research, the leading business intelligence provider, has released its latest research
|
more...
|
$3,500.00
|
|
Orphan Disease Therapeutics Market to 2018 - Improved Understanding of Rare Diseases' Heterogeneity and Novel New Clinical Trial Designs to Foster Innovation
4/30/2012 | published by: GBI Research
Orphan Disease Therapeutics Market to 2018 - Improved Understanding of Rare Diseases' Heterogeneity and Novel New Clinical Trial Designs to Foster Innovation Summary GBI Research, the leading business intelligence provider, has released its latest research “Orphan Disease
|
more...
|
$3,500.00
|
|
Contract Manufacturing Organizations to 2018 - Cost Advantages and Improving Quality Standards Build Confidence and Encourage Foreign Investment in Asian CMOs
4/20/2012 | published by: GBI Research
Contract Manufacturing Organizations to 2018 - Cost Advantages and Improving Quality Standards Build Confidence and Encourage Foreign Investment in Asian CMOs Summary GBI Research, the leading business intelligence provider, has released its latest report, “Contract Manufacturing Organizations
|
more...
|
$3,500.00
|
|
Chinese Markets for Hepatitis Drugs
4/1/2012 | published by: Asia Market Information & Development Company
China's demand for hepatitis drugs has grown at a fast pace in the past decade. In the next five years, both production and demand will continue to grow. This new study examines China's economic
|
more...
|
$4,000.00
|
|
Kuwait Pharmaceuticals and Healthcare Report Q2 2012
3/20/2012 | published by: Business Monitor International
BMI View: While Kuwait will continue to be of interest to multinational drugmakers – on account oftraditional preference for branded medicines and the population’s wealth – we caution that strengtheningregional harmonisation will make for an
|
more...
|
$1,175.00
|
|
Spain Pharmaceuticals and Healthcare Report Q2 2012
3/20/2012 | published by: Business Monitor International
BMI View: Companies with significant exposure to debt-ridden European markets will be hard hit bygovernment austerity measures across the region, particularly by pharmaceutical price erosionmechanisms. The Spanish government’s austerity measures look set to continue to
|
more...
|
$1,175.00
|
Related Markets
Pricing Reports
- Pricing and Reimbursement in Generics - European Austerity Measures and Healthcare Cost Containment Puts Innovation-Driven Pharma Companies under Pressure
- Pricing and Reimbursement in Russia - Big Pharma Take Advantage of Reimbursement for Costly Drugs Through the DLO’s Seven Nosologies Program
- Pricing and Reimbursement of the Healthcare System in India - Low Levels of Drug Reimbursement Lead to a High Out-Of-Pocket Expenditure
- The Royalty Rate Report 2012: A Comprehensive Assessment of Valuation in the Pharmaceutical Sector
- Pharmaceutical Pricing Strategies – Changing Approaches to Meet Challenging Times
